NZ787824A - Method of treating lower tract urothelial cancer - Google Patents

Method of treating lower tract urothelial cancer

Info

Publication number
NZ787824A
NZ787824A NZ787824A NZ78782417A NZ787824A NZ 787824 A NZ787824 A NZ 787824A NZ 787824 A NZ787824 A NZ 787824A NZ 78782417 A NZ78782417 A NZ 78782417A NZ 787824 A NZ787824 A NZ 787824A
Authority
NZ
New Zealand
Prior art keywords
antimetabolite
individual
bladder
gemcitabine
agent
Prior art date
Application number
NZ787824A
Other languages
English (en)
Inventor
Dennis Giesing
Christopher Cutie
Purnanand Sarma
Cheryl Larrivee-Elkins
Christopher Searcy
Vikas Agarwal
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of NZ787824A publication Critical patent/NZ787824A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/02General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Epoxy Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
NZ787824A 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer NZ787824A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US201762443614P 2017-01-06 2017-01-06
NZ748252A NZ748252A (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Publications (1)

Publication Number Publication Date
NZ787824A true NZ787824A (en) 2025-10-31

Family

ID=60203435

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ787786A NZ787786A (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer
NZ748252A NZ748252A (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer
NZ787824A NZ787824A (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ787786A NZ787786A (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer
NZ748252A NZ748252A (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Country Status (23)

Country Link
US (1) US20190388338A1 (enExample)
EP (2) EP4209221A1 (enExample)
JP (3) JP7712055B2 (enExample)
KR (2) KR102435709B1 (enExample)
CN (2) CN118453872A (enExample)
AU (1) AU2017261371B2 (enExample)
CA (1) CA3023274A1 (enExample)
ES (1) ES2940227T3 (enExample)
FI (1) FI3452053T3 (enExample)
HR (1) HRP20221544T1 (enExample)
HU (1) HUE060965T2 (enExample)
IL (2) IL262746B (enExample)
LT (1) LT3452053T (enExample)
MX (2) MX389296B (enExample)
NZ (3) NZ787786A (enExample)
PL (1) PL3452053T3 (enExample)
PT (1) PT3452053T (enExample)
RS (1) RS64032B1 (enExample)
RU (2) RU2022100624A (enExample)
SG (2) SG11201809838VA (enExample)
SI (1) SI3452053T1 (enExample)
SM (1) SMT202300047T1 (enExample)
WO (1) WO2017193098A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
AU2018306299B2 (en) * 2017-07-25 2024-08-08 Taris Biomedical Llc Methods of treating tumor metastasis
SG11202003950WA (en) 2017-11-08 2020-05-28 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
JP5913095B2 (ja) 2009-06-26 2016-04-27 タリス バイオメディカル エルエルシー 植込み型薬物送達装置及びその作製方法
EP3884988B1 (en) 2009-12-17 2025-06-18 TARIS Biomedical LLC Implantable device with intravesical tolerability
MX343671B (es) * 2010-06-02 2016-11-16 Abraxis Bioscience Llc * Metodos de tratamiento de cancer de vejiga.
EP2600800B1 (en) 2010-08-05 2020-09-30 TARIS Biomedical LLC Ureteral stent drug delivery device and kit
CA2825399A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
KR20190134832A (ko) * 2012-03-29 2019-12-04 알토 바이오사이언스 코포레이션 종양 형성 치료방법
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
SI2890384T1 (sl) * 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
US10137287B2 (en) 2013-03-05 2018-11-27 Taris Biomedical Llc Drug delivery devices and methods for controlled drug release through device orifice
JP6517186B2 (ja) 2013-03-15 2019-05-22 タリス バイオメディカル エルエルシー 薬物透過性構成部材を備えた薬物送達デバイス、及び方法
CA2902556C (en) 2013-03-15 2021-06-22 Heejin Lee Drug delivery devices and methods for drug delivery
CA2919215C (en) 2013-08-19 2022-11-29 Taris Biomedical Llc Multi-unit drug delivery devices and methods
MX2016011333A (es) * 2014-03-06 2016-12-07 Taris Biomedical Llc Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
JP6856380B2 (ja) 2014-06-26 2021-04-07 タリス バイオメディカル エルエルシー 弾性ポリマー−薬物マトリックス系を含む膀胱内薬物送達デバイス及び方法
US10894150B2 (en) 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods

Also Published As

Publication number Publication date
AU2017261371A1 (en) 2018-12-13
RU2018142908A (ru) 2020-06-08
WO2017193098A1 (en) 2017-11-09
BR112018072551A2 (pt) 2019-02-19
RS64032B1 (sr) 2023-04-28
EP4209221A1 (en) 2023-07-12
SG11201809838VA (en) 2018-12-28
PT3452053T (pt) 2023-03-03
EP3452053A1 (en) 2019-03-13
HUE060965T2 (hu) 2023-04-28
CN109475571A (zh) 2019-03-15
RU2764747C2 (ru) 2022-01-20
CA3023274A1 (en) 2017-11-09
JP2019514970A (ja) 2019-06-06
MX2018013432A (es) 2019-08-12
RU2022100624A (ru) 2022-02-09
KR20220123317A (ko) 2022-09-06
ES2940227T3 (es) 2023-05-04
FI3452053T3 (fi) 2023-04-12
IL262746B (en) 2022-09-01
RU2018142908A3 (enExample) 2020-08-31
LT3452053T (lt) 2023-02-10
US20190388338A1 (en) 2019-12-26
JP2024028881A (ja) 2024-03-05
MX2021013461A (es) 2021-12-10
JP7712055B2 (ja) 2025-07-23
KR102435709B1 (ko) 2022-08-25
HRP20221544T1 (hr) 2023-02-17
EP3452053B1 (en) 2022-12-14
EP3452053A4 (en) 2019-12-25
SMT202300047T1 (it) 2023-03-17
SG10201913416PA (en) 2020-03-30
CN118453872A (zh) 2024-08-09
MX389296B (es) 2025-03-20
IL295592A (en) 2022-10-01
KR20190005204A (ko) 2019-01-15
IL262746A (en) 2018-12-31
NZ748252A (en) 2025-10-31
SI3452053T1 (sl) 2023-03-31
PL3452053T3 (pl) 2023-05-08
NZ787786A (en) 2025-10-31
AU2017261371B2 (en) 2023-07-06
JP2022009327A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
JP2024028881A (ja) 下部尿路上皮がんを処置する方法
US12059428B2 (en) Methods of treating tumor metastasis
KR102892737B1 (ko) 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
HK40005970A (en) Method of treating lower tract urothelial cancer
HK40005970B (en) Method of treating lower tract urothelial cancer
BR122024005298A2 (pt) Usos de antimetabólitos no tratamento de câncer urotelial do trato inferior, kits e dispositivo de liberação
BR112018072551B1 (pt) Kits para tratamento de câncer de bexiga músculo invasivo
RU2799546C2 (ru) Способы лечения метастаза опухоли